electroCore, Inc. Announces Additions to Board of Directors in Connection with Recently Completed Initial Public Offering

BASKING RIDGE, N.J., July 10, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Carrie S. Cox as Chairman of its Board of Directors, and Michael G. Atieh and Stephen L. Ondra, M.D. as recent additions to the Board.

"We are pleased to have three distinguished members join our Board of Directors in conjunction with our recently completed initial public offering, each of whose impressive pharmaceutical and business experience is invaluable to the company’s continued growth and expansion," said Frank Amato, Chief Executive Officer, electroCore. “Further, we look forward to having Ms. Cox lend her extensive leadership experience and depth of expertise with companies in electroCore’s stage of commercialization as Chairman.”

Ms. Cox brings three decades of experience in the pharmaceutical industry to her role as Chairman. Ms. Cox most recently served as Chief Executive Officer of Humacyte, Inc. and previously as President, Global Pharmaceuticals, at Schering-Plough Corporation from 2003 until its merger with Merck & Co., Inc. in November 2009. Ms. Cox was responsible for the company’s global prescription pharmaceutical business, which generated approximately $16 billion in annual sales. Ms. Cox has been named six times to Fortune’s list of the “50 Most Powerful Women in Business” and her work has been featured in Harvard Business Review.

Mr. Atieh spent the majority of his career in the biotechnology and pharmaceutical industries, including 20 years at Merck & Co., Inc. Prior to his retirement in 2016, Mr. Atieh was Executive Vice President, Chief Financial and Business Officer at Ophthotech, Inc. (Nasdaq:OPHT), a biotechnology company. Mr. Atieh currently serves on the Board of Directors of Chubb Limited (NYSE:CB) where he is a member of the Risk and Finance Committee, and previously served as the Chair of the Audit Committee from 2012 until May 2018. His previous public company board experience includes Theravance Biopharma and OSI Pharmaceuticals, where he also served as Chair of the Audit Committee.

Dr. Ondra is Chief Executive Officer of North Star Healthcare Consulting, a healthcare technology consulting company that he founded in 2017. He previously served as Senior Vice President and Chief Medical Officer of Health Care Service Corporation, the largest customer-owned health insurance company in the United States. In 2009, Dr. Ondra was appointed by President Obama as Senior Policy Advisor for Health Affairs of the U.S. Department of Veterans Affairs, and was assigned to the Executive Office of the President of the United States from 2010 to 2012.

Commenting on her Chairman appointment, Ms. Cox said, “I am honored to be joining the electroCore Board of Directors during a pivotal time in the company’s history. I look forward to working with my fellow directors and becoming a part of the electroCore team, furthering a commitment to shifting the treatment paradigm and providing patients with a safer solution for managing pain.”

These Board appointments complement several recent milestones for electroCore. In conjunction with its initial public offering, the company's common stock began trading on the Nasdaq Global Market under the symbol ECOR on June 22, 2018, and was uplisted to the Nasdaq Global Select Market on June 25, 2018. In addition, the company’s platform therapy gammaCore™ (nVNS) received a second U.S. Food and Drug Administration (FDA) clearance in January 2018 for the acute treatment of pain associated with migraine in adults. gammaCore is also cleared by the FDA for the acute treatment of pain associated with episodic cluster headache in adults.

electroCore’s Board of Directors consists of senior executives from the business, pharmaceutical, medical devices and medicine sectors. Members of the Board include: Frank Amato, Chief Executive Officer of electroCore; J.P. Errico, Chief Science & Strategy Officer of electroCore; Thomas J. Errico, M.D., Professor of Orthopedic and Neurological Surgery, NYU School of Medicine; Michael G. Atieh, former Executive Vice President, Chief Financial and Business Officer at Ophthotech, Inc.; Nicholas Colucci, Chairman, Publicis Health; Carrie S. Cox, Executive Chairman and former Chief Executive Officer of Humacyte, Inc.; Trevor Moody, Partner, M.H. Carnegie & Co. and President, TM Strategic Advisors LLC; Stephen L. Ondra, M.D., Chief Executive Officer of North Star Healthcare Consulting; and James L. L. Tullis, Chief Executive Officer of Tullis Health Investors.

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the acute treatment of migraine and episodic cluster headache.


Greg Chodaczek or Lynn Lewis
Gilmartin Group
(646) 924-1769


Alexandra Canale
GCI Health
(617) 921-9353

Photos accompanying this announcement are available at:




You May Also Like

CytomX Therapeutics Appoints Marion McCourt to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...

Biodesix Announces PD-L1 Collaboration with Professor Fred R. Hirsch

BOULDER, Colo., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Biodesix® announced a new collaboration agreement ...

Mateon Therapeutics Reports First Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), ...